Skip to main content
. 2019 Mar 13;54(8):752–761. doi: 10.1007/s00535-019-01569-7

Fig. 3.

Fig. 3

SVR12 by comorbidities and co-medications. Efficacy of 8-week G/P treatment, defined as SVR12, is reported by comorbidity (ab) and co-medications (c) using an ITT analysis. GERD, gastroesophageal reflux disease; CKD, chronic kidney disease; CCB calcium channel blockers, ARB angiotensin receptor blockers, PPI proton-pump inhibitors